New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis

Osteoporosis International

Volumn 6, Issue 4, 1996, Pages 297-302

  Guerrero, R ^a   Diaz Martin, M A ^a   Diaz Diego, E M ^a   Disla, Turbi ^b   Rapado, A ^b   De la Piedra, C ^a,c  

^a Fund Jiménez Díaz   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c Clínica Nuestra Señora de la Concepción   (Spain)

Author keywords

Bone resorption markers; CTX; Hydroxyproline; ICTP; Postmenopausal osteoporosis; Pyridinoline

Indexed keywords

25 HYDROXYVITAMIN D; BIOCHEMICAL MARKER; CALCIUM; COLLAGEN TYPE 1; CREATININE; ETIDRONIC ACID; HYDROXYPROLINE; PEPTIDE; PYRIDINOL;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; COLLAGEN METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; HYDROXYPROLINE URINE LEVEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

EID: 0029772346     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01623388     Document Type: Article

References (28)

1. Seyedin SM, Kung VT, Daniloff YN, et al. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993;8:635-41.
2. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994;9:1643-9.
3. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptides of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
4. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N- telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
5. Bonde M, Qvist P, Fledelins C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clio Chem 1994;40:2024-5
6. Delmas PD. Biochemical markers of bone turnover. J Bone Miner Res 1993:8 (Suppl 2):S549-55.
7. Kivirikko KI, Laitinen O, Procop OJ. Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 1967;19:249-55.
8. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
9. Eyre D. Editorial. New biomarkers of bone resorption. J Clin Endocrinol Metab 1992;74:470A-B.
10. Hamdy NA, Papapoulos SE, Colwell A, Eastell R, Russell RG. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paaet's disease of bone? Bone Miner 1993:22:1-8.
11. Rapado A, De la Piedra C. Torres R. BGP (osteocalcin, bone Gla protein) in involutional osteoporosis. Clin Rheumatol 1988;Suppl 2:1-5
12. Gunja-Smith Z, Boucek R. Collagen cross-linking compounds in human unne. Biochem J 1981;197:759-62.
13. Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinium crosslinks of collagen. Trends Endocrinol Metab 1992;3:263-70.
14. Uebelhart D, Gineyts E, Chapuy MC, Delmas PH. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
15. Fledelius C, Riis BJ, Overgaard K, Christiansen C. The diagnostic validity of urinary free pyridinolines to identify women at risk of osteoporosis. Calcif Tissue Int 1994;54:381-4.
16. Mole PA, Walkinshaw MH, Robins SP, et al. Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause? Eur J Clin Invest 1992;22:767-71.
17. Seibel MJ, Ratcliffe A, Cosman F. Urinary hydroxypyridinium crosslinks of collagen are markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. Trans Orthop Res Soc 1991;16:279-81.
18. McLaren AM, Hordon LD, Bird HA, et al. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis 1992;51:648-51.
19. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 1991;72:367-73.
20. Eastell R, Robins SP, Colwell T, Assiri AMA, Riggs BL, Russell RGG. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporosis Int 1993;3:255-60.
21. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (Cross-Laps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
22. Hassager C, Jensen LT, Podenphant J, Thomsen K, Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 1994;54:30-3.
23. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994;24:81-94.
24. Kassem M, Brixen K, Blum WF, Mosekilde L, Eriksen EF. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis. J. Bone Miner Res 1994;9:1365-70.
25. Hassager C, Risteli J, Christiansen C. Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen. Osteoporosis Int 1994;4:349-52.
26. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
27. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resporption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780-5.
28. Garnero P, Gyneyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995;10:641-9.